Moreover, the combination of clinicopathological factors associated with GAD1 expression in prostate cancer to create a prognostic nomogram revealed that the combined index better evaluated patients' PFI (C-index = 0.782, p = 1.94e−14) (Fig. 3I). This evidence concerns the gene GAD1 and prostate carcinoma.